Hints That Experimental Drug Might Curb a Form of ALS

FRIDAY, Sept. 23, 2022 (HealthDay News) -- People with a rare genetic form of ALS may benefit from extended use of an investigational drug, a new study shows.

The medication, tofersen, benefited patients with mutations of the gene SOD1. These mutations create a misfolded version of a protein, which leads to amyotrophic lateral sclerosis, also known as Lou Gehrig's disease.

Originally published on consumer.healthday.com, part of the TownNews Content Exchange.